^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSLN positive

    i
    Other names: MSLN, CAK1, MPF, Mesothelin
    Entrez ID:
    10232
    Related biomarkers:
    Expression
    Others
    Apply
    Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCI-2018-01503) (NCT03587311)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    10/12/2018
    Primary completion :
    10/21/2024
    Completion :
    10/21/2024
    MSLN
    |
    MSLN positive
    |
    Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCI10208) (NCT03816358)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    12/09/2019
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
    A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    07/19/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    MSLN
    |
    MSLN positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/15/2019
    Primary completion :
    11/02/2028
    Completion :
    11/02/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849)
    Phase 1/2
    TCR2 Therapeutics
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    06/21/2022
    Primary completion :
    10/30/2028
    Completion :
    10/30/2028
    MSLN
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/01/2024
    Initiation :
    02/06/2024
    Primary completion :
    12/18/2024
    Completion :
    12/18/2024
    MSLN
    |
    MSLN expression • MSLN positive
    |
    LMB-100
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    03/10/2023
    Primary completion :
    03/10/2026
    Completion :
    03/10/2033
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Mesothelin/GPC3/GUCY2C-CAR-T
    Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (NCT01393483)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/03/2023
    Initiation :
    03/01/2011
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    MSLN
    |
    MSLN expression • MSLN positive
    Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (NCT04727554)
    Phase 1
    Amgen
    Completed
    Last update posted :
    09/22/2023
    Initiation :
    04/29/2021
    Primary completion :
    06/05/2023
    Completion :
    06/05/2023
    MSLN
    |
    MSLN expression • MSLN positive
    |
    inezetamab (AMG994) • zeluvalimab (AMG 404)
    Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer (NCT05686720)
    Phase 1
    First Affiliated Hospital of Shantou University...
    Not yet recruiting
    Last update posted :
    01/16/2023
    Initiation :
    02/01/2023
    Primary completion :
    02/01/2024
    Completion :
    06/01/2024
    HER-2 • ER • PGR • MSLN
    |
    HER-2 negative • ER negative • MSLN positive • PGR negative
    |
    SZ011
    Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05141253)
    Phase 1
    Tongji Hospital
    Recruiting
    Last update posted :
    04/27/2022
    Initiation :
    01/12/2022
    Primary completion :
    11/01/2023
    Completion :
    11/01/2036
    MSLN
    |
    MSLN positive
    |
    RD133